Eribulin Monoclonal Antibody
-
中文名稱：Eribulin鼠單克隆抗體
-
貨號：CSB-MA943989I1m
-
規格：￥3000
-
圖片：
-
Eribulin antibody on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%. -
The Binding Activity of Farletuzumab ecteribulin (Synonyms: MORAb-202) with Anti-Eribulin antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Farletuzumab ecteribulin (Synonyms: MORAb-202) at 2 μg/mL can bind Anti-Eribulin antibody, the EC50 is 0.7244 to 1.019 ng/mL. -
The purity of Mouse Anti-Eribulin Antibody is more than 98% by SEC-HPLC.
-
-
其他：
產品詳情
-
產品描述：CUSABIO的Eribulin單克隆抗體，專為科研用途設計，可作為實驗室研究工具使用。抗體經Protein G純化工藝處理，純度達95%以上，亞型為IgG2b，能特異性識別Eribulin（Eribulin，又稱B1939、E7389、ER-0865262）。 產品采用ELISA檢測平臺驗證，適用于小鼠源樣本檢測。抗體溶液含50%甘油、0.01M PBS（pH 7.4）緩沖體系，并添加0.03% Proclin 300作為防腐劑，以維持抗體穩定性。 收到產品后，應立即儲存在-20°C或-80°C環境中，避免反復凍融影響抗體活性。該抗體僅用于科研實驗，不可用于臨床診斷或治療用途，建議在專業實驗室條件下操作使用。 注：本產品不含貨號信息，供貨周期為3個工作日，適用于Eribulin相關的生物學機制研究、藥物分析等科研場景，為生命科學研究提供可靠的免疫檢測工具。
-
基因名：Eribulin
-
別名：Eribulin, B1939, E7389, ER-086526
-
宿主：Mouse
-
反應種屬：Homo sapiens (Human)
-
免疫原：Eribulin-BSA
-
標記方式：Non-conjugated
-
克隆類型：Monoclonal
-
抗體亞型：IgG2b
-
純化方式：>95%, Protein G purified
-
克隆號：45C2G9
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 -
產品提供形式：Liquid
-
應用范圍：ELISA
-
Protocols：
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產品評價
Most popular with customers
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
-
